Selectively depolymerized galactomannan polysaccharide
View Patent ↗Disclosed herein are compositions and methods for treating diseases such as cancer. The compositions comprise one or more polysaccharides in an admixture with one or more therapeutic agents. This admixture can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered alone, can cause undesirable side-effects in the subject. The polysaccharide component minimizes or eliminates these side effects. The compositions described herein effectuate an enhanced therapeutic effect along with reduced toxicity.
1. A mixture, comprising
a first component comprising a parenteral administration vehicle,
a second component comprising a homogenous galactomannan oligosaccharide;
Wherein the homogenous galactomannan oligosaccharide has a ratio of mannose to galactose of about 1.7:1;
Wherein the homogenous galactomannan oligosaccharide consists essentially of galactose and mannose residues; and
wherein the homogenous galactomannan oligosaccharide results from a sufficiently controlled depolymerization of galactomannan so as to result in a homogenous galactomannan polysaccharide having an average molecular weight of about 4,000 to about 60,000 daltons as assayed by GPC-MALLS.
2. The formulation of claim 1 , wherein said homogenous galactomannan oligosaccharide is a β-1,4-D-galactomannan.
3. The formulation of claim 2 , wherein said homogenous galactomannan oligosaccharide is (((1,4)-linked β-D-mannopyranose) 17 -((1,6)-linked-β-D-galactopyranose) 10 ) 12 ).
4. The formulation of claim 1 , wherein the homogenous galactomannan oligosaccharide is a galectin antagonist.
5. The formulation of claim 1 , wherein the homogenous galactomannan oligosaccharide is further comprised of exposed galactose residues capable of interacting with biological targets.
6. The formulation of claim 1 , wherein the homogenous galactomannan oligosaccharide is further capable of interacting with regulatory sites in a biological system governed by galactose-specific residues.
7. The formulation of claim 1 , wherein the parenteral administration vehicle is an oily vehicle.
8. The formulation of claim 1 , wherein the parenteral administration vehicle is an aqueous vehicle.
9. The formulation of claim 1 , wherein the parenteral administration vehicle further comprises formulatory agents.
10. The formulation of claim 9 , wherein the formulatory agent is a suspending agent.
11. The formulation of claim 9 , wherein the formulatory agent is a stabilizing agent.
12. The formulation of claim 9 , wherein the formulatory agent is a dispersing agent.